» Articles » PMID: 33916811

A New Method for Improving Extraction Efficiency and Purity of Urine and Plasma Cell-Free DNA

Overview
Specialty Radiology
Date 2021 Apr 30
PMID 33916811
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

This study assessed three commercially available cell-free DNA (cfDNA) extraction kits and the impact of a PEG-based DNA cleanup procedure (DNApure) on cfDNA quality and yield. Six normal donor urine and plasma samples and specimens from four pregnant (PG) women carrying male fetuses underwent extractions with the JBS cfDNA extraction kit (kit J), MagMAX Cell-Free DNA Extraction kit (kit M), and QIAamp Circulating Nucleic Acid Kit (kit Q). Recovery of a PCR product spike-in, endogenous TP53, and Y-chromosome DNA was used to assess kit performance. Nucleosomal-sized DNA profiles varied among the kits, with prominent multi-nucleosomal-sized peaks present in urine and plasma DNA isolated by kits J and M only. Kit J recovered significantly more spike-in DNA than did kits M or Q ( < 0.001) from urine, and similar amounts from plasma ( = 0.12). Applying DNApure to kit M- and Q-isolated DNA significantly improved the amplification efficiency of spike-in DNA from urine ( < 0.001) and plasma ( ≤ 0.013). Furthermore, kit J isolated significantly more Y-chromosome DNA from PG urine compared to kit Q ( = 0.05). We demonstrate that DNApure can provide an efficient means of improving the yield and purity of cfDNA and minimize the effects of pre-analytical biospecimen variability on liquid biopsy assay performance.

Citing Articles

The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples.

Peng H, Pan M, Zhou Z, Chen C, Xing X, Cheng S Front Cell Dev Biol. 2024; 12:1385041.

PMID: 38784382 PMC: 11111958. DOI: 10.3389/fcell.2024.1385041.


Concentration strategies for spiked and naturally present biomarkers in non-invasively collected first-void urine.

Teblick L, Lipovac M, Burdier F, De Smet A, Bell M, van den Borst E Eur J Med Res. 2024; 29(1):131.

PMID: 38368382 PMC: 10873940. DOI: 10.1186/s40001-024-01719-5.


Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.

Lin S, Xia W, Kim A, Chen D, Schleyer S, Choi L Sci Rep. 2023; 13(1):21585.

PMID: 38062093 PMC: 10703769. DOI: 10.1038/s41598-023-48500-y.


Impact of Cell-Debris and Room-Temperature Storage on Urine Circulating Tumor DNA from Hepatocellular Carcinoma.

Kim A, Lin S, Wang Z, Luu H, Hamilton J, Song W J Mol Diagn. 2023; 25(12):913-920.

PMID: 37813297 PMC: 10734279. DOI: 10.1016/j.jmoldx.2023.08.006.


Methods for the purification and detection of single nucleotide KRAS mutations on extrachromosomal circular DNA in human plasma.

Hansen L, Jakobsen S, Zole E, Noer J, Fang L, Alizadeh S Cancer Med. 2023; 12(17):17679-17691.

PMID: 37602814 PMC: 10523981. DOI: 10.1002/cam4.6385.


References
1.
Markus H, Contente-Cuomo T, Farooq M, Liang W, Borad M, Sivakumar S . Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018; 8(1):7375. PMC: 5943304. DOI: 10.1038/s41598-018-25810-0. View

2.
Jain S, Su Y, Su Y, McCloud S, Xue R, Lee T . Characterization of the hepatitis B virus DNA detected in urine of chronic hepatitis B patients. BMC Gastroenterol. 2018; 18(1):40. PMC: 5857095. DOI: 10.1186/s12876-018-0767-1. View

3.
Lin S, Linehan J, Wilson T, Hoon D . Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers. Eur Urol Focus. 2017; 3(2-3):265-272. DOI: 10.1016/j.euf.2017.03.009. View

4.
Lin S, Dhillon V, Jain S, Chang T, Hu C, Lin Y . A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J Mol Diagn. 2011; 13(5):474-84. PMC: 3157622. DOI: 10.1016/j.jmoldx.2011.05.005. View

5.
Tsui N, Jiang P, Chow K, Su X, Leung T, Sun H . High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One. 2012; 7(10):e48319. PMC: 3485143. DOI: 10.1371/journal.pone.0048319. View